Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

Sand_Pebble Apr. 30 at 3:31 PM

$AVXL okay, 4 new 13F sec filings on Fintel. One of them decreased holdings, other 3 held. Our institutional ownership is now 40.75%. Fintel does calculate in real time as they post. Not an end of day thing.

0 · Reply

Rudedog_1963 Apr. 30 at 2:50 PM

$AVXL $$$ANAVEX$$$

0 · Reply

DragonAlgo Apr. 30 at 1:41 PM

🐉 $AVXL CALL — DragonAlgo® Signal Contract: AVXL CALL Expiry: 2026-05-15 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.10 Stop: $0.07 TP1: $0.13 TP2: $0.17 TP3: $0.24 🔗 https://dragonalgo.com

0 · Reply

bigbiobooom Apr. 30 at 12:56 PM

$AVXL Missling should’ve been fired in March 25th, 2026. This is sitting at $.88 cents before reverse split and he added 65M shares of dilution achieving ZERO approvals. FDA already told him he needs a REAL phase 3 which will require 1000 patients and cost between $200-300M in dilution. He gambled and failed at all levels with the EMA and the FDA already told him don’t even try…

1 · Reply

AntonioChigurh Apr. 30 at 12:41 PM

$AVXL Missling still hiding. Doesn’t even want to send next proxy event email. He can sit idle all year, still banking huge. Expect more dilution soon.

0 · Reply

Sand_Pebble Apr. 30 at 12:37 PM

$AVXL concerning institutional ownership the jury is still out. 40.27% currently. Fintel shows the 13K filings keep rolling in, 5 yesterday. https://fintel.io/so/us/avxl

3 · Reply

Sand_Pebble Apr. 30 at 12:09 PM

$AVXL If I had a lot of realized gains from other investments I would have lightened my Anavex position after the rejection & later with the withdraw. I fear that is what institutional investors have done. We will see leading up to May 15th, the deadline tutes have to report. If my fears are reality then we might see further sp decline as sheep follow the shepherds. If I’m wrong, which is often the case, and institutional ownership has stayed the same or increased, then we hopefully get back into the 4's again.

1 · Reply

Tunken Apr. 30 at 11:48 AM

$AVXL At some point they will have to announce the annual meeting and proxy material.

1 · Reply

Steppenwoelfin Apr. 30 at 9:58 AM

$AVXL

0 · Reply

Georgejj Apr. 30 at 3:52 AM

$AVXL Fed Holds Steady https://investorshub.advfn.com/market-news/article/27511/fed-holds-steady-amid-historic-dissent-as-wall-street-awaits-big-tech-earnings-blitz Good luck and GOD bless ,

0 · Reply

Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 7:30 AM EDT - 16 days ago

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease

Apr 7, 2026, 7:30 AM EDT - 23 days ago

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 30, 2026, 7:30 AM EDT - 4 weeks ago

Anavex Life Sciences Provides Comprehensive Regulatory Update

Mar 25, 2026, 10:40 AM EDT - 5 weeks ago

Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback

Mar 25, 2026, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

Mar 23, 2026, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease

Mar 20, 2026, 7:30 AM EDT - 5 weeks ago

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease

Mar 17, 2026, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference

Mar 3, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Mar 2, 2026, 11:50 AM EST - 2 months ago

Anavex Life Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Feb 23, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Feb 9, 2026, 8:30 AM EST - 2 months ago

Anavex Life Sciences Earnings Call Transcript: Q1 2026

Feb 9, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Feb 3, 2026, 7:30 AM EST - 3 months ago

Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

Jan 14, 2026, 7:30 PM EST - 3 months ago

Anavex Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 AM EST - 3 months ago

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

Jan 8, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

Jan 6, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program

Dec 24, 2025, 10:30 AM EST - 4 months ago

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Dec 18, 2025, 7:30 AM EST - 4 months ago

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Nov 26, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 25, 2025, 8:30 AM EST - 5 months ago

Anavex Life Sciences Earnings Call Transcript: Q4 2025

Nov 25, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Nov 19, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Nov 18, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Nov 14, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Oct 29, 2025, 7:30 AM EDT - 6 months ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 10, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 2, 2025, 7:35 AM EDT - 7 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 30, 2025, 8:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 1:00 PM EDT - 8 months ago

Anavex Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Anavex Life Sciences Earnings Call Transcript: Q3 2025

Aug 12, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 14, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q2 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Anavex Life Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 5, 2025, 11:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 9:50 AM EST - 1 year ago

Anavex Life Sciences Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:30 AM EST - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q1 2025

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 16, 2025, 12:00 PM EST - 1 year ago

Anavex Life Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 23, 2024, 8:30 AM EST - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q4 2024

Dec 4, 2024, 3:25 PM EST - 1 year ago

Anavex Life Sciences Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Sep 9, 2024, 11:30 AM EDT - 1 year ago

Anavex Life Sciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q3 2024

Jun 27, 2024, 7:00 AM EDT - 2 years ago

Anavex Life Sciences Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 20, 2024, 10:00 AM EDT - 2 years ago

Anavex Life Sciences Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 9, 2024, 8:30 AM EDT - 2 years ago

Anavex Life Sciences Earnings Call Transcript: Q2 2024

Apr 8, 2024, 8:45 AM EDT - 2 years ago

Anavex Life Sciences Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 4, 2024, 1:30 PM EST - 2 years ago

Anavex Life Sciences Transcript: TD Cowen 44th Annual Health Care Conference

Feb 7, 2024, 8:30 AM EST - 2 years ago

Anavex Life Sciences Earnings Call Transcript: Q1 2024

Jan 11, 2024, 1:30 PM EST - 2 years ago

Anavex Life Sciences Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 27, 2023, 8:30 AM EST - 2 years ago

Anavex Life Sciences Earnings Call Transcript: Q4 2023

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Anavex Life Sciences Earnings Call Transcript: Q3 2023

Feb 7, 2023, 8:30 AM EST - 3 years ago

Anavex Life Sciences Earnings Call Transcript: Q1 2023

Jan 12, 2023, 11:15 AM EST - 3 years ago

Anavex Life Sciences Transcript: JPMorgan Healthcare Conference

Dec 5, 2022, 8:30 AM EST - 3 years ago

Anavex Life Sciences Transcript: Status Update

Nov 28, 2022, 8:30 AM EST - 3 years ago

Anavex Life Sciences Earnings Call Transcript: Q4 2022

Aug 9, 2022, 5:00 PM EDT - 4 years ago

Anavex Life Sciences Earnings Call Transcript: Q3 2022

May 10, 2022, 8:45 AM EDT - 4 years ago

Anavex Life Sciences Earnings Call Transcript: Q2 2022

Feb 9, 2022, 3:52 AM EST - 4 years ago

Anavex Life Sciences Earnings Call Transcript: Q1 2022

Feb 1, 2022, 8:30 AM EST - 4 years ago

Anavex Life Sciences Transcript: Study Result

Jan 10, 2022, 8:30 AM EST - 4 years ago

Anavex Life Sciences Transcript: Study Result

Aug 12, 2021, 11:58 AM EDT - 5 years ago

Anavex Life Sciences Earnings Call Transcript: Q3 2021

May 13, 2021, 2:33 AM EDT - 5 years ago

Anavex Life Sciences Earnings Call Transcript: Q2 2021

Sand_Pebble Apr. 30 at 3:31 PM

0 · Reply

Rudedog_1963 Apr. 30 at 2:50 PM

$AVXL $$$ANAVEX$$$

0 · Reply

DragonAlgo Apr. 30 at 1:41 PM

0 · Reply

bigbiobooom Apr. 30 at 12:56 PM

1 · Reply

AntonioChigurh Apr. 30 at 12:41 PM

$AVXL Missling still hiding. Doesn’t even want to send next proxy event email. He can sit idle all year, still banking huge. Expect more dilution soon.

0 · Reply

Sand_Pebble Apr. 30 at 12:37 PM

$AVXL concerning institutional ownership the jury is still out. 40.27% currently. Fintel shows the 13K filings keep rolling in, 5 yesterday. https://fintel.io/so/us/avxl

3 · Reply

Sand_Pebble Apr. 30 at 12:09 PM

1 · Reply

Tunken Apr. 30 at 11:48 AM

$AVXL At some point they will have to announce the annual meeting and proxy material.

1 · Reply

Steppenwoelfin Apr. 30 at 9:58 AM

$AVXL

0 · Reply

Georgejj Apr. 30 at 3:52 AM

$AVXL Fed Holds Steady https://investorshub.advfn.com/market-news/article/27511/fed-holds-steady-amid-historic-dissent-as-wall-street-awaits-big-tech-earnings-blitz Good luck and GOD bless ,

0 · Reply

J903625 Apr. 30 at 12:41 AM

$AVXL THE LOST DECADE: A Masterclass in Mismanagement & Lies The shorts WON and Shkreli called it. For ten years, shareholders were fed a narrative built on "super-massaged" data on Blarcamesine only for the reality to finally set in with 2 CHMP rejections. Missling didn't just miss the mark—he led investors down a path of engineered optimism that resulted in a total wipeout of capital and time. To those who held on: the "recovery" isn't coming. This is the end of the line for a decade of broken promises and Regeneron nor Biogen will come and save you. RIP all that passed away believing Missling lies and those who will never see any return on their investment. @4RingsPatsRule P.S. Now we know why he never invested his own money on this POS. Even Tom Bishop called him out.

1 · Reply

BioGLovesMe Apr. 29 at 9:48 PM

$AVXL I see the permabaggies are onto the next delusion to stay "invested." Regeneron? Really? You can't make this stuff up. Georgejii when will the Regeneron partnership news drop? This can be your new catalyst you'll never be right about. Dog bless Missleading.

1 · Reply

kitty7kitty Apr. 29 at 7:11 PM

$AVXL I wish Anavex would just sell Blarcamesine over the counter at this point through Amazon. Why not?

2 · Reply

Georgejj Apr. 29 at 6:30 PM

$AVXL Any and all posters referring to AVXL stock as a scam is obviously a basher or a FUDster or a shorter.

2 · Reply

DueBill Apr. 29 at 6:17 PM

$AVXL please tell us how you know these things to be factual?

1 · Reply

pumperstomper Apr. 29 at 5:24 PM

$AVXL shut this scam down SEC wtf

0 · Reply

Sand_Pebble Apr. 29 at 4:56 PM

$AVXL me & my 30.9k Anavex shares.

5 · Reply

AntonioChigurh Apr. 29 at 4:29 PM

$AVXL Be happy. Wait 10 more years. Have Low expectations on Management.

0 · Reply

Tunken Apr. 29 at 3:02 PM

$AVXL Missling is not accountable and does not hold his employees accountable. He does not communicate with shareholders, regulators or employeed. Shake it up foundation offered to pay for half of PD trial two years ago and nothing. They are in the dark. All of us in the same boat.

1 · Reply

bigbiobooom Apr. 29 at 2:04 PM

$AVXL people desperate praying for a lifesaver when Director of Business Development and Investor Relations still on vacations. Missling runs this company like a scam. Sorry for all the bagholders and all the incoming dilution.

0 · Reply

papatrick Apr. 29 at 1:27 PM

$AVXL The Missling Piece life vest.. MPLV

0 · Reply

Series4Guy Apr. 29 at 1:23 PM

$AVXL Here’s the most promising part of this “investment “ right now - The ability to design a confirmatory trial based on data gleaned from the phase 2b/3 trial! Apart from that the company must be more transparent and less arrogant. I’m hearing there’s not going to be a partnership until after an agency decision.

2 · Reply

Market Cap	312.31M
Revenue (ttm)	0.00
Net Income (ttm)	-46.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	618,600
Avg Vol	1,442,034
Day's Range	N/A - N/A
Shares Out	92.67M
Stochastic %K	6%
Beta	1.18
Analysts	Sell
Price Target	$22.00